PCSK9 Inhibitors Market Driven by Cardiovascular Disease Prevalence

agregó una foto Health

2025-05-22 08:51:56 -

PCSK9 inhibitors are a class of lipid-lowering biologics designed to target proprotein convertase subtilisin/kexin type 9, offering a potent reduction in low-density lipoprotein (LDL) cholesterol for patients at high cardiovascular risk. Administered via subcutaneous injection, these monoclonal antibodies and small molecules block PCSK9 interaction with LDL receptors, enhancing receptor...

0 Commentarios 0 Acciones 61 Views 0 Vista previa